Intrinsic resistance to the MEK1/2 inhib
β
Kathryn Balmanno; Simon D. Chell; Annette S. Gillings; Shaista Hayat; Simon J. C
π
Article
π
2009
π
John Wiley and Sons
π
French
β 466 KB
## Abstract Mutations in __KRAS__ or __BRAF__ frequently manifest in constitutive activation of the MEK1/2βERK1/2 signalling pathway. The MEK1/2βselective inhibitor, AZD6244 (ARRYβ142886), blocks ERK1/2 activation and is currently undergoing clinical evaluation. Tumour cells can vary markedly in th